TurnSole Announces Regulatory Authority Approval and Subsequent Initiation of a Phase Ib/II Trial to evaluate the efficacy and the ...
PÉCS, Hungary and BUDAPEST, Hungary, March 04, 2021 (GLOBE NEWSWIRE) -- TurnSole Biologics (TurnSole) today announced the start of a Phase I/II open-label study for Azacytidine, initiated with a lead-in dose escalation pharmacokinetic Phase I/b part in …